Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(natalizumab)
2,422 results
  • Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity. [Case Reports]
    Ann Clin Transl Neurol 2019De Masi R, Orlando S, De Donno A
  • The comorbidity between multiple sclerosis (MS) and progressive familial intrahepatic cholestasis type-3 (PFIC3) has never been described yet. ABCB4 gene encodes the multidrug resistant protein 3 (MDR3) and its mutations induce PFIC3 as well as intrahepatic cholestasis of pregnancy (ICP) and drug-induced liver injury (DILI). We describe the case of a 32-year-old female with MS and PFIC3 who was e…
  • Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. [Review]
    Curr Treat Options Neurol 2019; 21(10):50Macaron G, Feng J, … Rensel M
  • With the recognition that pediatric-onset multiple sclerosis (POMS) is characterized by more prominent disease activity, earlier age at onset of disability milestones, and more prominent cognitive impairment compared with physical disability earlier in the disease course compared with adult-onset multiple sclerosis (AOMS), there has been increasing interest in identifying optimal and safe treatme…
  • Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis. [Journal Article]
    Mult Scler J Exp Transl Clin 2019 Jul-Sep; 5(3):2055217319875471Margoni M, Rinaldi F, … Gallo P
  • We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16-17 years) were followed for a median of 3.9 years (interquartile range 3.1-5.0). At a natalizumab bre…
New Search Next